International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer
“HCC is a devastating disease with a poor prognosis, affecting an estimated 850,000 people globally,” said Dr.
Prof. Lencioni’s presentation, “Rethinking Our Approach to Intermediate-Size HCC” focused on the increasing incidence and burden of HCC globally, the limited overall survival benefit with current therapies at later stages of disease progression, and the potential for ThermoDox® to provide enhanced survival benefit with standardized radiofrequency ablation (RFA).
“ThermoDox® is the first treatment candidate for HCC designed for image-guided drug delivery to be tested in a large, multicenter Phase III trial,” said Prof. Lencioni. “Post-hoc analyses of the first Phase III study of ThermoDox® – the HEAT Study – generated important findings that demonstrated its potential to meaningfully increase overall survival when target tissue is adequately heated with RFA for 45 minutes or longer. These analyses showed that ThermoDox® treatment with prolonged RFA heating can increase doxorubicin tissue concentration and could extend overall survival to more than two years. The company’s ongoing second Phase III study, the OPTIMA Study, is designed to test this survival benefit hypothesis. If this hypothesis bears out in the OPTIMA Study, this would be very meaningful and highly encouraging as there are few available treatments effective in prolonging survival in HCC.”
Celsion’s Phase III OPTIMA Study is expected to enroll up to 550 patients in up to 70 clinical sites in
“HCC is a disease characterized by high mortality and an increasing prevalence globally. Patients with primary liver cancer are underserved by current treatments, and
The slides from Prof. Lencioni’s presentation, “Rethinking Our Approach to Intermediate-Size HCC,” are available on Celsion’s corporate website at www.celsion.com.
About the OPTIMA Study
The Phase III OPTIMA Study is expected to enroll up to 550 patients in up to 70 clinical sites in
About Celsion Corporation
ThermoDox is a registered trademark of
Celsion Investor Contact
Jeffrey W. ChurchSr. Vice President and CFO 609-482-2455 firstname.lastname@example.org
Source: Celsion Corporation